Indeed, immunotherapy responsiveness can be explained and predicted thanks to the combination of two independent elements: the “hot” or “cold” status, according to the range of inflammatory cell infiltration and IFN-γ signature, and the tumor mutation burden, which can lead to neoantigen expression. The gene discussed is IFNG; the disease is neoplasm.